Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334472 · ClinicalTrials.gov registry record
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 105
- Enrollment target
NCT05334472: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05334472 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05334472 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
Primary Outcome
Proportion of respondents (patients and care partners) in top two rating categories (satisfied and extremely satisfied) for device satisfaction on use of KESIMPTA Sensoready®
Interventions
- OTHER Kesimpta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-11-24 |
| Est. Completion | 2023-02-15 |
What the finished NCT05334472 record still lists
NCT05334472 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Kesimpta is the first listed.
NCT05334472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05334472 about?
NCT05334472 is a clinical study titled "A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis". This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
What is the current status of trial NCT05334472?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2021-11-24. Estimated completion is 2023-02-15.
What interventions are being tested in trial NCT05334472?
The interventions under investigation include: Kesimpta (OTHER).
Who is sponsoring clinical trial NCT05334472?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI